(Adnkronos) - “Vericiguat è un farmaco intelligente con un meccanismo d’azione innovativo, diverso da quello dei farmaci finora impiegati nel trattamento dell’insufficienza cardiaca, che stimola l’attività dell'enzima guanilato ciclasi solubile (sGC)”. Così Pasquale Perrone Filardi, presidente Società italiana di Cardiologia (Sic), parlando del nuovo farmaco di Bayer che ha ottenuto la rimborsabilità da parte di Aifa, in occasione della conferenza stampa organizzata dalla società farmaceutica a Milano.
Category
🗞
NewsTranscript
00:00 (upbeat music)
00:02 (speaking in foreign language)
00:08 (speaking in foreign language)
00:12 (speaking in foreign language)
00:16 (speaking in foreign language)
00:20 (speaking in foreign language)
00:24 (speaking in foreign language)
00:28 (speaking in foreign language)
00:32 (speaking in foreign language)
00:35 (speaking in foreign language)
00:39 (speaking in foreign language)
00:43 (speaking in foreign language)
00:47 (speaking in foreign language)
00:51 (speaking in foreign language)
00:56 (dog barking)
00:59 (speaking in foreign language)
01:02 (speaking in foreign language)
01:06 (speaking in foreign language)
01:10 (speaking in foreign language)
01:14 (speaking in foreign language)
01:18 (speaking in foreign language)
01:22 (speaking in foreign language)
01:26 (speaking in foreign language)
01:30 (speaking in foreign language)
01:34 (speaking in foreign language)
01:38 (speaking in foreign language)
01:42 (speaking in foreign language)
01:46 (speaking in foreign language)
01:50 (speaking in foreign language)
01:53 (speaking in foreign language)
01:57 of patients who today suffer from this important pathology.